Christoph Minichsdorfer1, Oskar Steinbrecher1, Marita KÖlz2, Maximilian Schmid3, Markus Raderer1, Thomas Brodowicz1, Wolfgang Lamm4. 1. Clinical Division of Oncology, Department of Medicine I, Medical University of Vienna - General Hospital, Vienna, Austria. 2. Department of Pathology, Medical University of Vienna - General Hospital, Vienna, Austria. 3. Department of Radiation Oncology, Medical University of Vienna - General Hospital, Vienna, Austria. 4. Clinical Division of Oncology, Department of Medicine I, Medical University of Vienna - General Hospital, Vienna, Austria; wolfgang.lamm@meduniwien.ac.at.
Abstract
BACKGROUND/AIM: Ewing sarcoma (ES) and osteosarcomas (OSA) are the most common bone tumor types in adolescents and young adults (AYA). Therapy management of these tumors consists of preoperative chemotherapy, operation, and postoperative chemotherapy. The aim of this study was to evaluate the efficacy and tolerability of EURAMOS-A and EURO E.W.I.N.G. protocols. PATIENTS AND METHODS: We retrospectively evaluated 31 patients between 18 and 39 years of age with ES and OSA treated at the Department of Medicine I, Clinical Division of Oncology. Patients with ES were treated according the EURO E.W.I.N.G protocol, whereas patients with OSA according to the EURAMOS-1 protocol. RESULTS: Most frequent tumor sites for ES were thorax and pelvis, each 33%. Eight patients had initially localized disease (67%). A median of 3 cycles of full dose chemotherapy could be administered. Nine patients had a dose reduction (75%). Most common reason for dose reduction was prolonged aplasia (67%). Overall response rate (ORR) was 33%. For OSA patients, the most frequent tumor site was the lower extremity (58%). Sixteen patients (84%) had initially localized disease. A median of only 9 cycles of EURAMOS-1 in full dose could be administered. Most common reason for dose reduction was elevated methotrexate level (53%) and ORR was 90%. CONCLUSION: The two studied protocols were well-tolerated in the AYA patients included in this study. Dose reductions instead of dose delays should be considered when side effects occur. Copyright
BACKGROUND/AIM: Ewing sarcoma (ES) and osteosarcomas (OSA) are the most common bone tumor types in adolescents and young adults (AYA). Therapy management of these tumors consists of preoperative chemotherapy, operation, and postoperative chemotherapy. The aim of this study was to evaluate the efficacy and tolerability of EURAMOS-A and EURO E.W.I.N.G. protocols. PATIENTS AND METHODS: We retrospectively evaluated 31 patients between 18 and 39 years of age with ES and OSA treated at the Department of Medicine I, Clinical Division of Oncology. Patients with ES were treated according the EURO E.W.I.N.G protocol, whereas patients with OSA according to the EURAMOS-1 protocol. RESULTS: Most frequent tumor sites for ES were thorax and pelvis, each 33%. Eight patients had initially localized disease (67%). A median of 3 cycles of full dose chemotherapy could be administered. Nine patients had a dose reduction (75%). Most common reason for dose reduction was prolonged aplasia (67%). Overall response rate (ORR) was 33%. For OSA patients, the most frequent tumor site was the lower extremity (58%). Sixteen patients (84%) had initially localized disease. A median of only 9 cycles of EURAMOS-1 in full dose could be administered. Most common reason for dose reduction was elevated methotrexate level (53%) and ORR was 90%. CONCLUSION: The two studied protocols were well-tolerated in the AYA patients included in this study. Dose reductions instead of dose delays should be considered when side effects occur. Copyright
Authors: A Cangir; T J Vietti; E A Gehan; E O Burgert; P Thomas; M Tefft; M E Nesbit; J Kissane; D Pritchard Journal: Cancer Date: 1990-09-01 Impact factor: 6.860
Authors: Marie-Cécile Le Deley; Michael Paulussen; Ian Lewis; Bernadette Brennan; Andreas Ranft; Jeremy Whelan; Gwénaël Le Teuff; Jean Michon; Ruth Ladenstein; Perrine Marec-Bérard; Henk van den Berg; Lars Hjorth; Keith Wheatley; Ian Judson; Heribert Juergens; Alan Craft; Odile Oberlin; Uta Dirksen Journal: J Clin Oncol Date: 2014-06-30 Impact factor: 44.544
Authors: Christine Juergens; Claire Weston; Ian Lewis; Jeremy Whelan; Michael Paulussen; Odile Oberlin; Jean Michon; Andreas Zoubek; Herbert Juergens; Alan Craft Journal: Pediatr Blood Cancer Date: 2006-07 Impact factor: 3.167
Authors: E A Eisenhauer; P Therasse; J Bogaerts; L H Schwartz; D Sargent; R Ford; J Dancey; S Arbuck; S Gwyther; M Mooney; L Rubinstein; L Shankar; L Dodd; R Kaplan; D Lacombe; J Verweij Journal: Eur J Cancer Date: 2009-01 Impact factor: 9.162